One-carbon Therapeutics are taking their previous success of discovering the PARP inhibitor concept for the treatment of BRCA mutated cancer to a new level; exploiting cancer-specific metabolism to target the DDR, and cause cancer-specific DNA damage at replication forks.
One-carbon therapeutics has secured seed funding and is already now interested in establishing relationship with VCs potentially interested in syndication in an A series investment round.